MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
BCRX — BioCryst Pharmaceuticals Inc
NasdaqBioCryst Pharmaceuticals Inc
$8.17
+0.05(+0.62%)
- O
- 8.12
- H
- 8.20
- L
- 7.92
- V
- 5.87M
⏱️ End-of-day dataAs of Oct 2, 2026
BioCryst Pharmaceuticals Inc Statistics
Total Valuation
| Market Cap | $2.20B |
| Enterprise Value | $2.26B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | 255.54M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -31.30 |
| EV / Sales | n/a |
| EV / EBITDA | -32.26 |
| EV / EBIT | -32.23 |
| EV / FCF | -36.33 |
Financial Position
| Current Ratio | 1.91 |
| Quick Ratio | n/a |
| Debt / Equity | -1.47 |
| Debt / EBITDA | -1.16 |
| Debt / FCF | -1.31 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | 130.33% |
| Return on Assets (ROA) | -155.21% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-165,934 |
| Employee Count | 435 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | $1.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | +11.46% |
| 50-Day Moving Average | $9.22 |
| 200-Day Moving Average | $8.68 |
| Relative Strength Index (RSI) | 48.24 |
| Average Volume (20 Days) | 5,935,760 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | $15.10M |
| Operating Income | -$70.16M |
| Pretax Income | -$72.08M |
| Net Income | -$72.18M |
| EBITDA | -$70.03M |
| EBIT | -$70.10M |
| Loss Per Share | $-2.98 |
Balance Sheet
| Cash & Cash Equivalents | $17.16M |
| Total Debt | $81.47M |
| Net Cash | -$64.31M |
| Net Cash Per Share | $-0.25 |
| Equity (Book Value) | -$55.38M |
| Book Value Per Share | $-0.22 |
| Working Capital | $17.82M |
Cash Flow
| Operating Cash Flow | -$7.99M |
| Capital Expenditures | -$403.00K |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -$62.19M |
| FCF Per Share | $-0.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | -2.83% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |